Repligen (RGEN) Tops Q4 EPS by 21c, Offers FY Guidance

Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.52, $0.21 better than the analyst estimate of $0.31. Revenue for the quarter came in at $108.6 million versus the consensus estimate of $93.88 million.

GUIDANCE:

Repligen sees FY2021 EPS of $1.86-$1.94, versus the consensus of $1.65. Repligen sees FY2021 revenue of $500-525 million, versus the consensus of $459.5 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49